格隆汇9月19日丨沃森生物(300142.SZ)公布，公司子公司北京沃森创新生物技术有限公司、云南疫苗实 验室有限公司、玉溪沃森生物技术有限公司联合复旦大学、上海蓝鹊生物医药有限公司（简称"蓝鹊生 物"）联合研发的冻干带状疱疹病毒mRNA疫苗向国家药品监督管理局申请临床试验，并于近日获得 《受理通知书》。本疫苗为沃森生物联合蓝鹊生物、复旦大学共同基于自主研发建立的"mRNA疫苗技 术平台"开发，接种本疫苗后，可刺激机体产生抗带状疱疹病毒的免疫力，用于预防带状疱疹。 ...

每经AI快讯，9月19日，沃森生物(300142.SZ)公告称，公司子公司联合研发的冻干带状疱疹病毒mRNA 疫苗向国家药品监督管理局申请临床试验，并于近日获得受理通知书。该疫苗由沃森生物、蓝鹊生物、 复旦大学共同基于自主研发的"mRNA疫苗技术平台"开发，用于预防带状疱疹。目前全球已上市的带状 疱疹疫苗主要为减毒活疫苗和重组疫苗，尚无mRNA技术路线的带状疱疹疫苗上市。临床试验申请获得 受理后，需经批准后方可开展临床试验，对公司本年度经营业绩不会产生重大影响。 ...

Core Viewpoint - Yunnan Watson Bio's application for clinical trials of its respiratory syncytial virus mRNA vaccine has been accepted by the National Medical Products Administration, marking a significant step in its development [1][2]. Group 1: Company Information - The vaccine is developed in collaboration with Fudan University, Shanghai Bluebird Biomedicine Co., Ltd., and its subsidiaries, aiming to stimulate immune responses against respiratory syncytial virus (RSV) [2]. - The vaccine is classified as a preventive biological product under the registration category 1.2 [1]. Group 2: Industry Context - Three RSV vaccines have been approved and are currently available in foreign markets, including GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA, with global sales reaching approximately $4 billion [2]. - The acceptance of the clinical trial application does not significantly impact the company's operating performance for the current year [2].

Core Viewpoint - Watson Bio, in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., has applied for clinical trials for its respiratory syncytial virus (RSV) mRNA vaccine, receiving acceptance notification from the National Medical Products Administration [1] Company Summary - The vaccine is developed based on an independently established mRNA vaccine technology platform, aimed at stimulating immune response against RSV to prevent lower respiratory tract diseases caused by RSV infection [1] - Watson Bio has partnered with Blue Magpie Biopharmaceutical and Fudan University for the development of this vaccine [1] Industry Summary - Currently, three RSV vaccines have been approved and launched internationally: GSK's Arexvy (recombinant protein vaccine), Pfizer's Abrysvo (recombinant protein vaccine), and Moderna's mRESVIA (mRNA1345, mRNA vaccine) [1] - There are no approved RSV vaccines in the domestic market, indicating a potential opportunity for Watson Bio [1] - The global sales for RSV vaccines are projected to be approximately $4 billion for the 2023-2024 fiscal year [1]

Core Viewpoint - Watson Bio (300142.SZ) has announced that its mRNA vaccine for respiratory syncytial virus, developed in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals, has been accepted for clinical trial application by the National Medical Products Administration [1] Group 1 - The mRNA vaccine is based on an independently developed "mRNA vaccine technology platform" aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus infection [1] - Currently, there are no approved vaccines for this indication in China, while three have been approved overseas [1] - The acceptance of the clinical trial application will require further approval before clinical trials can commence, and it is not expected to have a significant impact on the company's operating performance for the current year [1]

Core Viewpoint - Watson Bio has applied for clinical trials of its respiratory syncytial virus mRNA vaccine, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd, which has been accepted by the National Medical Products Administration [1] Group 1 - The mRNA vaccine is based on an independently developed "mRNA vaccine technology platform" aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus infections [1] - Currently, there are no approved vaccines for this indication in China, while three have been approved abroad [1] - The acceptance of the clinical trial application will require further approval before clinical trials can commence, and it is not expected to have a significant impact on the company's operating performance for the current year [1]